Brain glutamate and gamma-aminobutyric acid levels across COVID-19 lockdowns in patients with recurrent major depressive disorder and healthy individuals
Abstract The coronavirus disease 2019 (COVID-19) led to substantial social restriction measures. Social isolation has been demonstrated to promote psychiatric symptoms and to dysregulate gamma-aminobutyric acid (GABA) and glutamate levels. The aim of this investigation was to observe brain GABA and...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-05734-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849402854677151744 |
|---|---|
| author | Valentin Popper Benjamin Spurny-Dworak Jakob Unterholzner Murray Reed Theresa Wechsler Alexander Kautzky Peter Stöhrmann Manfred Klöbl Andreas Mühlberger Richard Frey Dan Rujescu Rupert Lanzenberger Thomas Vanicek |
| author_facet | Valentin Popper Benjamin Spurny-Dworak Jakob Unterholzner Murray Reed Theresa Wechsler Alexander Kautzky Peter Stöhrmann Manfred Klöbl Andreas Mühlberger Richard Frey Dan Rujescu Rupert Lanzenberger Thomas Vanicek |
| author_sort | Valentin Popper |
| collection | DOAJ |
| description | Abstract The coronavirus disease 2019 (COVID-19) led to substantial social restriction measures. Social isolation has been demonstrated to promote psychiatric symptoms and to dysregulate gamma-aminobutyric acid (GABA) and glutamate levels. The aim of this investigation was to observe brain GABA and glutamate concentrations and depressive symptom severity in association to lockdowns in patients with recurrent major depression disorder (rMDD) and healthy individuals (HI). In this longitudinal study, 18 patients with rMDD (11 female: 37.0 ± 10.0years) and 28 HI (16 female, 28.1 ± 5.0years) underwent three magnetic resonance spectroscopy imaging (MRSI) measurements over multiple lockdowns. Ratios of GABA+ (GABA + macromolecules) and glutamate + glutamine (Glx) to total creatinine (tCr) as well as GABA+/Glx ratios were calculated for subcortical regions and the insula. Depressive symptom severity and social support were assessed at each visit. Lockdowns did not significantly change neurotransmitter ratios in individual brain regions (all p corrected > 0.05). Further, no significant changes in Beck’s Depression Inventory II (BDI-II) scores occurred along the lockdowns (all p corrected > 0.05). Our results may be explained by ceiling effects of the beginning of the pandemic and the first lockdown, by good social support during the pandemic in HI and a small sample size. Patients with rMDD reported an insufficient social support, suggesting a special vulnerability to social isolation due to pandemics. |
| format | Article |
| id | doaj-art-4e5eb219fe9d423fa1eba75be6dbf5ab |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-4e5eb219fe9d423fa1eba75be6dbf5ab2025-08-20T03:37:27ZengNature PortfolioScientific Reports2045-23222025-07-0115111010.1038/s41598-025-05734-2Brain glutamate and gamma-aminobutyric acid levels across COVID-19 lockdowns in patients with recurrent major depressive disorder and healthy individualsValentin Popper0Benjamin Spurny-Dworak1Jakob Unterholzner2Murray Reed3Theresa Wechsler4Alexander Kautzky5Peter Stöhrmann6Manfred Klöbl7Andreas Mühlberger8Richard Frey9Dan Rujescu10Rupert Lanzenberger11Thomas Vanicek12Department of Psychiatry and Psychotherapy, Medical University of ViennaDepartment of Psychiatry and Psychotherapy, Medical University of ViennaDepartment of Psychiatry and Psychotherapy, Medical University of ViennaDepartment of Psychiatry and Psychotherapy, Medical University of ViennaDepartment for Psychology, Clinical Psychology and Psychotherapy, University of RegensburgDepartment of Psychiatry and Psychotherapy, Medical University of ViennaDepartment of Psychiatry and Psychotherapy, Medical University of ViennaDepartment of Psychiatry and Psychotherapy, Medical University of ViennaDepartment for Psychology, Clinical Psychology and Psychotherapy, University of RegensburgDepartment of Psychiatry and Psychotherapy, Medical University of ViennaDepartment of Psychiatry and Psychotherapy, Medical University of ViennaDepartment of Psychiatry and Psychotherapy, Medical University of ViennaDepartment of Psychiatry and Psychotherapy, Medical University of ViennaAbstract The coronavirus disease 2019 (COVID-19) led to substantial social restriction measures. Social isolation has been demonstrated to promote psychiatric symptoms and to dysregulate gamma-aminobutyric acid (GABA) and glutamate levels. The aim of this investigation was to observe brain GABA and glutamate concentrations and depressive symptom severity in association to lockdowns in patients with recurrent major depression disorder (rMDD) and healthy individuals (HI). In this longitudinal study, 18 patients with rMDD (11 female: 37.0 ± 10.0years) and 28 HI (16 female, 28.1 ± 5.0years) underwent three magnetic resonance spectroscopy imaging (MRSI) measurements over multiple lockdowns. Ratios of GABA+ (GABA + macromolecules) and glutamate + glutamine (Glx) to total creatinine (tCr) as well as GABA+/Glx ratios were calculated for subcortical regions and the insula. Depressive symptom severity and social support were assessed at each visit. Lockdowns did not significantly change neurotransmitter ratios in individual brain regions (all p corrected > 0.05). Further, no significant changes in Beck’s Depression Inventory II (BDI-II) scores occurred along the lockdowns (all p corrected > 0.05). Our results may be explained by ceiling effects of the beginning of the pandemic and the first lockdown, by good social support during the pandemic in HI and a small sample size. Patients with rMDD reported an insufficient social support, suggesting a special vulnerability to social isolation due to pandemics.https://doi.org/10.1038/s41598-025-05734-2 |
| spellingShingle | Valentin Popper Benjamin Spurny-Dworak Jakob Unterholzner Murray Reed Theresa Wechsler Alexander Kautzky Peter Stöhrmann Manfred Klöbl Andreas Mühlberger Richard Frey Dan Rujescu Rupert Lanzenberger Thomas Vanicek Brain glutamate and gamma-aminobutyric acid levels across COVID-19 lockdowns in patients with recurrent major depressive disorder and healthy individuals Scientific Reports |
| title | Brain glutamate and gamma-aminobutyric acid levels across COVID-19 lockdowns in patients with recurrent major depressive disorder and healthy individuals |
| title_full | Brain glutamate and gamma-aminobutyric acid levels across COVID-19 lockdowns in patients with recurrent major depressive disorder and healthy individuals |
| title_fullStr | Brain glutamate and gamma-aminobutyric acid levels across COVID-19 lockdowns in patients with recurrent major depressive disorder and healthy individuals |
| title_full_unstemmed | Brain glutamate and gamma-aminobutyric acid levels across COVID-19 lockdowns in patients with recurrent major depressive disorder and healthy individuals |
| title_short | Brain glutamate and gamma-aminobutyric acid levels across COVID-19 lockdowns in patients with recurrent major depressive disorder and healthy individuals |
| title_sort | brain glutamate and gamma aminobutyric acid levels across covid 19 lockdowns in patients with recurrent major depressive disorder and healthy individuals |
| url | https://doi.org/10.1038/s41598-025-05734-2 |
| work_keys_str_mv | AT valentinpopper brainglutamateandgammaaminobutyricacidlevelsacrosscovid19lockdownsinpatientswithrecurrentmajordepressivedisorderandhealthyindividuals AT benjaminspurnydworak brainglutamateandgammaaminobutyricacidlevelsacrosscovid19lockdownsinpatientswithrecurrentmajordepressivedisorderandhealthyindividuals AT jakobunterholzner brainglutamateandgammaaminobutyricacidlevelsacrosscovid19lockdownsinpatientswithrecurrentmajordepressivedisorderandhealthyindividuals AT murrayreed brainglutamateandgammaaminobutyricacidlevelsacrosscovid19lockdownsinpatientswithrecurrentmajordepressivedisorderandhealthyindividuals AT theresawechsler brainglutamateandgammaaminobutyricacidlevelsacrosscovid19lockdownsinpatientswithrecurrentmajordepressivedisorderandhealthyindividuals AT alexanderkautzky brainglutamateandgammaaminobutyricacidlevelsacrosscovid19lockdownsinpatientswithrecurrentmajordepressivedisorderandhealthyindividuals AT peterstohrmann brainglutamateandgammaaminobutyricacidlevelsacrosscovid19lockdownsinpatientswithrecurrentmajordepressivedisorderandhealthyindividuals AT manfredklobl brainglutamateandgammaaminobutyricacidlevelsacrosscovid19lockdownsinpatientswithrecurrentmajordepressivedisorderandhealthyindividuals AT andreasmuhlberger brainglutamateandgammaaminobutyricacidlevelsacrosscovid19lockdownsinpatientswithrecurrentmajordepressivedisorderandhealthyindividuals AT richardfrey brainglutamateandgammaaminobutyricacidlevelsacrosscovid19lockdownsinpatientswithrecurrentmajordepressivedisorderandhealthyindividuals AT danrujescu brainglutamateandgammaaminobutyricacidlevelsacrosscovid19lockdownsinpatientswithrecurrentmajordepressivedisorderandhealthyindividuals AT rupertlanzenberger brainglutamateandgammaaminobutyricacidlevelsacrosscovid19lockdownsinpatientswithrecurrentmajordepressivedisorderandhealthyindividuals AT thomasvanicek brainglutamateandgammaaminobutyricacidlevelsacrosscovid19lockdownsinpatientswithrecurrentmajordepressivedisorderandhealthyindividuals |